GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SIGA Technologies Inc (NAS:SIGA) » Definitions » Cash Conversion Cycle

SIGA Technologies (SIGA Technologies) Cash Conversion Cycle : 971.17 (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is SIGA Technologies Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

SIGA Technologies's Days Sales Outstanding for the three months ended in Mar. 2024 was 70.43.
SIGA Technologies's Days Inventory for the three months ended in Mar. 2024 was 929.65.
SIGA Technologies's Days Payable for the three months ended in Mar. 2024 was 28.91.
Therefore, SIGA Technologies's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 971.17.


SIGA Technologies Cash Conversion Cycle Historical Data

The historical data trend for SIGA Technologies's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SIGA Technologies Cash Conversion Cycle Chart

SIGA Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 136.39 192.41 369.51 508.30 612.56

SIGA Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 886.05 823.05 1,212.20 344.41 971.17

Competitive Comparison of SIGA Technologies's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, SIGA Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SIGA Technologies's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SIGA Technologies's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where SIGA Technologies's Cash Conversion Cycle falls into.



SIGA Technologies Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

SIGA Technologies's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=86.79+551.4-25.63
=612.56

SIGA Technologies's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=70.43+929.65-28.91
=971.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SIGA Technologies  (NAS:SIGA) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


SIGA Technologies Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of SIGA Technologies's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


SIGA Technologies (SIGA Technologies) Business Description

Traded in Other Exchanges
N/A
Address
31 East 62nd Street, New York, NY, USA, 10065
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.
Executives
Evan A. Knisely director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Jay Varma director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Ford Harold Eugene Jr. director 4921 WILLIAM ARNOLD ROAD, MEMPHIS TN 38117
James Antal director 30952 STEEPLECHASE DRIVE, SAN JUAN CAPISTRANO CA 92675
Holly L. Phillips director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Gary J. Nabel director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Julian Nemirovsky director 35 EAST 62ND STREET, NEW YORK NY 10065
Edward P. Taibi director 35 EAST 62ND STREET, NEW YORK NY 10065
Jaymie A Durnan director C/O SIGA TECHNOLOGIES, INC.,, 31 EAST 62ND STREET, NEW YORK NY 10065
Gomez Phillip Louis Iii officer: Chief Executive Officer 7220 VAN NESS COURT, MCLEAN VA 22101
Daniel J Luckshire officer: Executive VP & CFO C/O SIGA TECHNOLOGIES, INC., 35 EAST 62ND STREET, NEW YORK NY 10065
Paul G Savas director 35 EAST 62ND STREET, NEW YORK NY 10021
Julie Kane director 77 BEALE ST, P.O. BOX 770000, SAN FRANCISCO CA 94177
Dennis E Hruby officer: Chief Scientific Officer SIGA TECHNOLOGIES, INC., 420 LEXINGTON AVENUE, SUITE 601, NEW YORK NY 10170
Michael J Bayer director 1100 N GLEBE ROAD, ARLINGTON VA 22201

SIGA Technologies (SIGA Technologies) Headlines

From GuruFocus